Regulatory round-up: 22 June 2026

Regulators put safety and compliance in the foreground over the past week, with updates stretching from new prescribing guidance in the USA to product safety action in Asia-Pacific and Latin America. The US Food and Drug Administration approved Utebzi for complicated urinary tract infections, while Australia’s Therapeutic Goods Administration sharpened its public messaging on unapproved peptide products and prescription medicine advertising.

Several agencies used the week to tidy up regulatory expectations rather than make headline approvals. Swissmedic updated requirements around excipients and SEND datasets, the Pharmaceuticals and Medical Devices Agency in Japan posted new safety and review updates, and Taiwan’s regulator revised drug inspection and serious adverse reaction rules.